|
시장보고서
상품코드
2084725
트랜스티레틴 아밀로이드증 치료 시장 : 약제 유형별, 질환 유형별, 유통 채널별, 지역별Transthyretin Amyloidosis Treatment Market, By Drug Type, By Disease Type, By Distribution Channel, By Geography |
||||||
트랜스티레틴 아밀로이드증 치료제 시장은 2026년에 121억 달러 규모에 달할 것으로 추정되고 있으며, 2033년까지 204억 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 7.8%로 성장할 것으로 전망되고 있습니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 121억 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년 예측 기간의 CAGR : | 7.80% | 2033년 시장 규모 예측 : | 204억 달러 |
트랜스티레틴 아밀로이도시는 아밀로이드라고 불리는 단백질이 체내의 장기나 조직에 비정상적으로 축적되는 것을 특징으로 하는 드문 유전성 질환으로 서서히 진행됩니다. 트랜스티레틴 아밀로이드증에는 주로 ‘유전성 트랜스티레틴 아밀로이드증’과 ‘야생형 트랜스티레틴 아밀로이드증’이라는 두 가지 유형이 있습니다. 유전성 트랜스티레틴 아밀로이도시는 다시 다발성 신경병증형, 심근병증형, 그리고 혼합형으로 분류됩니다.
트랜스티레틴 아밀로이드증의 진단에는 영상 검사, 조직병리학적 검사, 분자·유전자 검사 등의 방법이 사용됩니다. 뇌성 나트륨 이뇨 펩티드의 N-말단 단편(NT-proBNP)이나 트로포닌 등의 심장 바이오마커는 아밀로이드 침착에 따라 심장 내에서 비정상적으로 높은 농도로 검출되며, 이 질환의 진단에 활용됩니다. 가족성 트랜스티레틴 아밀로이드증의 진단 시에는 트랜스티레틴 유전자의 변이에 관한 유전자 검사가 실시됩니다.
시장 역학
트랜스티레틴 아밀로이드증 치료를 목적으로 하는 새로운 치료법의 승인 및 출시는 예측 기간 중 시장 성장을 촉진하는 주요 요인이 될 것으로 예상됩니다. 2018년 10월, Eidos Therapeutics, Inc.는 ATTR 치료를 적응증으로 하는 자사 개발 후보 약물 AG10에 대해 미국 식품의약국(FDA)으로부터 희귀의약품 지정(Orphan Drug Designation)을 획득했습니다.
2018년 10월, Ionis Pharmaceuticals, Inc. 및 그 자회사인 Akcea Therapeutics Inc.는 유전성 트랜스티레틴 아밀로이드증(hATTR)을 앓고 있는 성인 환자의 1기 또는 2기 다발성 신경병증 치료제로서, TEGSEDITM(이노텔센 주사액)에 대한 캐나다 승인을 획득했습니다.
또한 트랜스티레틴 아밀로이드증을 치료하기 위해 개발중인 약물 중 가까운 시일 내에 승인을 획득할 약물이 더욱 늘어날 것으로 예상됩니다. 따라서 이러한 견실한 파이프라인이 시장 성장을 지원할 것으로 예상됩니다. 예를 들어 제약회사 글락소스미스클라인(GlaxoSmithKline plc.)은 아밀로이드증 치료제로 GSK2398852(항-SAP 단일클론 항체)와 GSK2315698(CPHPC)의 병용 요법인 데자미즈마브(2398852)†＋2315698†을 개발하고 있습니다. 현재, 본 제품은 2상 임상시험 단계에 있습니다.
본 조사의 주요 특징
- 이 보고서에서는 전 세계 트랜스티레틴 아밀로이드증 치료 시장에 대한 상세한 분석을 수행하고, 예측 기간(2026-2033년) 동안 시장 규모 및 연평균 성장률(CAGR)을 제시하고 있습니다.
- 또한 다양한 부문에서 잠재적인 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한 본 조사에서는 시장 촉진요인, 시장 억제요인, 기회, 신제품 출시 및 승인, 지역별 전망, 그리고 주요 기업이 채택하는 경쟁 전략에 관한 중요 인사이트도 제공하고 있습니다.
- 이 보고서에서는 다음 매개변수를 바탕으로 전 세계 트랜스티레틴 아밀로이드증 치료 시장의 주요 기업을 분석하고 있습니다. : 기업 개요, 재무 실적, 제품 포트폴리오, 사업 전개 지역, 유통 전략, 주요 발전 사항 및 전략.
- 이 보고서에서 도출된 인사이트는 기업의 마케팅 담당자 및 경영진이 향후 제품 출시, 기술 업그레이드, 시장 확대 및 마케팅 전략에 대해 충분한 정보를 바탕으로 의사결정을 내릴 수 있도록 해줍니다.
- '세계의 트랜스티레틴 아밀로이드증 치료 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입 기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자 여러분은 전 세계 트랜스티레틴 아밀로이드증 치료 시장을 분석하는 데 활용된 다양한 전략 매트릭스를 활용함으로써 의사결정을 원활하게 진행할 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 트랜스티레틴 아밀로이드증 치료 시장 : 약제 유형별, 2021-2033년
제5장 세계의 트랜스티레틴 아밀로이드증 치료 시장 : 질환 유형별, 2021-2033년
제6장 세계의 트랜스티레틴 아밀로이드증 치료 시장 : 유통 채널별, 2021-2033년
제7장 세계의 트랜스티레틴 아밀로이드증 치료 시장 : 지역별, 2021-2033년
제8장 경쟁 구도
제9장 섹션
KSATransthyretin Amyloidosis Treatment Market is estimated to be valued at USD 12.1 Bn in 2026 and is expected to reach USD 20.4 Bn by 2033, growing at a compound annual growth rate (CAGR) of 7.8% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 12.1 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 7.80% | 2033 Value Projection: | USD 20.4 Bn |
Transthyretin amyloidosis is a rare inherited and slowly progressive disease characterized by abnormal buildup of deposits of a protein called amyloid (amyloidosis) in the body's organs and tissues. Two main type of transthyretin amyloidosis includes hereditary transthyretin amyloidosis and wild type transthyretin amyloidosis. Hereditary transthyretin amyloidosis is further divided into polyneuropathy, cardiomyopathy, and mixed type.
Diagnosis of transthyretin amyloidosis includes approaches such as imaging, histopathology, and molecular and genetic testing. Cardiac biomarkers such as N-terminal fragment of brain natriuretic peptide (NT-proBNP) and troponin are present in abnormally high concentrations in the heart, following amyloid deposits that can be tested for diagnosis of the disease. Genetic testing for transthyretin gene mutations is performed in case of familial transthyretin amyloidosis diagnosis.
Market Dynamics
Approvals and launches of novel therapies for the treatment of transthyretin amyloidosis is expected to be a major factor driving the market growth over the forecast period. In October 2018, Eidos Therapeutics, Inc. received U.S. Food and Drug Administration (FDA) Orphan Drug Designation for its drug candidate AG10, indicated for the treatment of ATTR.
In October 2018, Ionis Pharmaceuticals, Inc. and its Akcea Therapeutics Inc., received approval for its drug TEGSEDITM (inotersen injection) in Canada for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR)
Furthermore, increasing number under development drugs for the treatment of transthyretin amyloidosis are expected to gain approval in the near future. Therefore, presence of such robust pipeline is expected to boost the market growth. For instance, GlaxoSmithKline plc. a pharmaceutical company, is developing dezamizumab (2398852)† +2315698†, a combination of GSK2398852 (anti-SAP mAb) and GSK2315698 (CPHPC) for the treatment of amyloidosis. Currently, the product is under phase 2 clinical trial.
Key features of the study
- This report provides in-depth analysis of the global transthyretin amyloidosis treatment market and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2026-2033)
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by key players
- It profiles key players in the global transthyretin amyloidosis treatment market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
- Key companies covered as a part of this study include, Alnylam Pharmaceuticals, Inc., Pfizer, Inc., Prothena Corporation Plc., GlaxoSmithKline Plc., Ionis Pharmaceuticals, Inc., Eidos Therapeutics, and SOM Innovation Biotech, S.L.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
- The global transthyretin amyloidosis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the global transthyretin amyloidosis treatment market
Market Segmentation
- By Drug Type (Revenue, USD Bn, 2021-2033)
- Tafamidis (Vyndaqel)
- Patisiran (ONPATTRO)
- Inotersen (TEGSEDI)
- Others
- By Disease Type (Revenue, USD Bn, 2021-2033)
- Hereditary Transthyretin Amyloidosis
- Polyneuropathy
- Cardiomyopathy
- Mixed Type
- Wild Type Amyloidosis
- By Distribution Channel (Revenue, USD Bn, 2021-2033)
- Hospital Pharmacies
- Specialty Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region (Revenue, USD Bn, 2021-2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Key Players
- Alnylam Pharmaceuticals, Inc.
- Pfizer, Inc.
- Prothena Corporation Plc.
- GlaxoSmithKline Plc.
- Ionis Pharmaceuticals, Inc.
- Eidos Therapeutics
- SOM Innovation Biotech, S.L.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Disease Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Product Approval
- Collaboration/Merge/Acquisition
- Regulatory Landscape
- PEST Analysis
- Porter's Five Forces Analysis
- Epidemiology
- Robust Pipeline Analysis
4. Global Transthyretin Amyloidosis Treatment Market, By Drug Type, 2021 - 2033, (USD Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
- Tafamidis (Vyndaqel)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Patisiran (ONPATTRO)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Inotersen (TEGSEDI)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
5. Global Transthyretin Amyloidosis Treatment Market, By Disease Type, 2021 - 2033, (USD Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hereditary Transthyretin Amyloidosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Polyneuropathy
- Cardiomyopathy
- Mixed Type
- Wild Type Amyloidosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
6. Global Transthyretin Amyloidosis Treatment Market, By Distribution Channel, 2021 - 2033, (USD Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Specialty Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
7. Global Transthyretin Amyloidosis Treatment Market, By Region, 2021 - 2033, (USD Billion)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (USD Billion)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Company Profile
- Alnylam Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Pfizer, Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Prothena Corporation Plc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- GlaxoSmithKline Plc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Ionis Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Eidos Therapeutics
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- SOM Innovation Biotech, S.L.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Alnylam Pharmaceuticals, Inc.
- Analyst Views
9. Section
- References
- Research Methodology
- About Us
